Source comparison
Does BPC-157 Help Diabetic Neuropathy Research: Comparison
BPC-157 NGF upregulation, VEGF-mediated angiogenesis, FAK-paxillin pathway activation 38% MNCV improvement, increased nerve fiber density, elevated MBP/NF200 expression in rodent models 43% reduction in mechanical allodynia, 51% reduction in DRG apoptosis (ani
This comparison does not assign a generated winner or score.
- BPC-157
- NGF upregulation, VEGF-mediated angiogenesis, FAK-paxillin pathway activation
- 38% MNCV improvement, increased nerve fiber density, elevated MBP/NF200 expression in rodent models
- 43% reduction in mechanical allodynia, 51% reduction in DRG apoptosis (animal studies)
- None. Zero published human trials as of 2026
- Most compelling preclinical neuropathy data for any peptide; regulatory status prevents human validation
- Alpha-Lipoic Acid
- Antioxidant; reduces oxidative stress from AGEs and polyol pathway activation
- Minimal. Primarily protective, not regenerative
- Modest pain improvement (15–20% in meta-analyses); symptom relief only
- Multiple human RCTs; 600mg daily standard dose
- FDA-recognized but limited regenerative capacity; addresses oxidative damage without nerve repair
- Gabapentin
- Calcium channel modulation (α2δ subunit); dampens aberrant nerve signaling
- None. Purely symptomatic
- 30–40% pain reduction in diabetic neuropathy trials
- Extensive human data; first-line neuropathic pain drug
- Proven symptom control; does not reverse nerve damage or improve conduction velocity
- Nerve Growth Factor (rhNGF)
- Direct NGF receptor agonism; stimulates axonal sprouting and Schwann cell activity
- Strong in preclinical models; Phase II human trials showed modest nerve density improvements
- Variable. Some trials showed benefit, others neutral
- Phase II completed; Phase III abandoned due to injection site hyperalgesia
- Biologics face delivery and tolerability challenges; systemic NGF causes severe side effects
- BPC-157's advantage over symptomatic drugs (gabapentin, duloxetine) is structural repair. Its advantage over NGF biologics is route flexibility and lack of severe adverse events in animal models. The critical limitation is absence of human safety and efficacy data. Every other row in this table has at least Phase II human trial results.